PsA GRAPPA domains: Outcomes With a JAKi

Save

Dr. Schwartzman and Dr. Ruderman discuss how PsA disease activity across GRAPPA domains may guide treatment decisions, sharing both the evidence for and their experience with a JAKi across domains.

5-Year Results of an IL-23 Inhibitor in Patients With PsA

Save

Dr. Alvin Wells and Dr. Shikha Singla share their clinical perspectives on using an IL–23 inhibitor to manage patients with PsA throughout their treatment journey in the context of 5-year data from the KEEPsAKE trial program.

The Impact of Obesity on Psoriatic Arthritis

Save

Image alt text: A person indoors raises one arm in a flexed pose while holding the elbow with the opposite hand. Is obesity common in your patients with PsA? Learn more about the intersection of disease pathogenesis between PsA and obesity and how weight intervention can affect PsA outcomes.

Advancing the Treatment Landscape for Pediatric Psoriatic Disease

Save

Learn more about a treatment offering pediatric patients 6 years and older who also weigh at least 40 kg, and their physicians and adult caregivers, an option that may improve skin clearance for moderate to severe plaque psoriasis or treat active psoriatic arthritis, collectively known as psoriatic disease.

Underserved and Under-treated

Save

Watch our Underserved and Under-Treated series as part of this month's Mission: APP Partners in Care campaign. Now available: Pain Management and Workforce & APPs

IL-23 Inhibition Across Psoriatic Disease* and Inflammatory Bowel Disease†

Save

Watch Dr. Khattri & Jennifer Labas, MSN, discuss IL-23 inhibition in adults with active PsA, moderate to severe plaque PsO, moderately to severely active UC, & moderately to severely active CD

Sjögren’s Disease – What Are You Missing?

Save

What could you be missing in Sjögren's disease? Explore hypothetical patient cases with atypical presentations, systemic manifestations, and overlooked symptoms. Gain expert insights and practical tips for clinical assessment from Dr Shereen Mahmood and learn how the ESSDAI can help you measure disease activity.

A JAKi in GCA: Phase 3 Results Through 2 Years

Save

Listen as rheumatologists Dr. Anisha Dua and Dr. Ben Boone discuss the latest efficacy and safety results over 2 years from a Phase 3 trial in GCA, including remission, flares, and glucocorticoid use in patients continuing vs withdrawing a JAKi"

A JAKi CHAT: Shared Decision-Making in RA

Save

Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.

ILD Treatment and Guidelines

Save

Watch our 11-video series on ILD Treatment and Guidelines including videos on assessing ILD, guidelines caveats and concerns, and more.

Structural damage progression in active PsA

Save

Watch Dr. Philip Mease discuss the impact of structural damage on active PsA and follow along as he reviews clinical trial data

Navigating the Path to SLE Remission

Save

Watch rheumatologists Dr Anca Askanase and Dr Cristina Arriens discuss their clinical perspectives on how to target and achieve DORIS remission in clinical practice.